Go Pro
Alec Stranahan

Alec Stranahan Analyst Performance

Biotechnology Equity Research at Bank of America

Alec Stranahan is a stock analyst at Bank of America in the medical sector, covering 12 publicly traded companies. Over the past year, Alec Stranahan has issued 17 stock ratings, including buy, hold, and sell recommendations. While full access to Alec Stranahan's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Alec Stranahan's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
20 Last 1 Years
Buy Recommendations
55.00% 11 Buy Ratings
Companies Covered
12 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy55.0%11 ratings
Hold30.0%6 ratings
Sell15.0%3 ratings

Out of 20 total stock ratings issued by Alec Stranahan at Bank of America, the majority (55.0%) have been Buy recommendations, followed by 30.0% Hold and 15.0% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
12 companies

Alec Stranahan, an analyst at Bank of America, currently covers 12 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
12 companies
100.0%

Alec Stranahan of Bank of America specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
10 companies
83.3%
MED - DRUGS
2 companies
16.7%

Alec Stranahan's Ratings History at Bank of America

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Erasca, Inc. stock logo
ERAS
Erasca
7/14/2026Boost Price Target$19.45$18.00Neutral
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
7/14/2026Boost Price Target$343.65$396.00Buy
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
7/8/2026Reiterated Rating$36.74$47.00Buy
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
7/7/2026Boost Price Target$37.39$46.00Buy
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
7/7/2026Lower Price Target$11.20$17.00Buy
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
7/7/2026Boost Price Target$56.06$20.00Underperform
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
6/12/2026Initiated Coverage$13.67$35.00Buy
Erasca, Inc. stock logo
ERAS
Erasca
6/4/2026Upgrade$13.18$16.00Neutral
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
3/27/2026Lower Price Target$6.43$21.00Buy
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
1/22/2026Boost Price Target$290.21$318.00Buy
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
10/17/2025Boost Price Target$188.33$255.00Buy
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
9/3/2025Downgrade$5.86$7.00Neutral
Xencor, Inc. stock logo
XNCR
Xencor
9/3/2025Downgrade$8.55$12.00Neutral
Erasca, Inc. stock logo
ERAS
Erasca
9/3/2025Reiterated Rating$1.60$1.00Underperform
Novavax, Inc. stock logo
NVAX
Novavax
8/20/2025Reiterated Rating$9.52$7.00Underperform
Novavax, Inc. stock logo
NVAX
Novavax
7/22/2025Lower Price Target$6.99$9.00Neutral
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
7/22/2025Lower Price Target$152.14$192.00Buy
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
3/28/2025Upgrade$22.19$42.00Buy
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
3/5/2025Lower Price Target$4.64$12.00Neutral
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
2/7/2025Initiated Coverage$7.80$15.00Buy